

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	5536902
<b>Application Number:</b>	10590575
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	8560
<b>Title of Invention:</b>	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
<b>First Named Inventor/Applicant Name:</b>	Jerome B. Zeldis
<b>Customer Number:</b>	84802
<b>Filer:</b>	Irina E. Britva/Eric Baclig
<b>Filer Authorized By:</b>	Irina E. Britva
<b>Attorney Docket Number:</b>	9516-335-999
<b>Receipt Date:</b>	17-JUN-2009
<b>Filing Date:</b>	22-AUG-2006
<b>Time Stamp:</b>	19:55:11
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		9516-335-999_Amendment.pdf	475511 c8d7a29ad6ac3faf9afcd4abfad2d8e61bd39ed5c	yes	13

	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment/Req. Reconsideration-After Non-Final Reject		1	1	
	Specification		2	2	
	Claims		3	7	
	Applicant Arguments/Remarks Made in an Amendment		8	13	
Warnings:					
Information:					
2	Foreign Reference	9516-335-999_B9.pdf	3402467	no	64
			692885537542b9ac78e2a676e3fde81cb25e982a		
Warnings:					
Information:					
3	Foreign Reference	9516-335-999_B10.pdf	1588985	no	44
			272e3617fc40f47091f29bea71cb7ed2d623195d		
Warnings:					
Information:					
4	NPL Documents	9516-335-999_C68.pdf	193193	no	4
			908971c16df829a7a9f8aac087b3d4af8989a329		
Warnings:					
Information:					
5	NPL Documents	9516-335-999_C69.pdf	145848	no	4
			cba5beaa6ab199388527364b683b021b19c66865		
Warnings:					
Information:					
6		9516-335-999_SupplDS.pdf	166416	yes	4
			e32e52c177ae7a76d7d36d2686e9f92966df962c		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Transmittal Letter		1	3	
	Information Disclosure Statement (IDS) Filed (SB/08)		4	4	
Warnings:					
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.